Objective. Accurate assessment of lupus flares is critical but problematic in clinical trials. This study examined the impact of modifications to the classic Safety of Estrogens in Lupus Erythematosus National Assessment (SELENA)-SLEDAI flare index (cSFI).
Introduction
Accurate, reproducible measurement of lupus flares is as important in clinical trials as detection of improvement since this provides a meaningful assessment of durability in treatment responses over time. The classic Safety of Estrogens in Lupus Erythematosus National Assessment (SELENA)-SLEDAI flare index (cSFI) was originally developed specifically for the SELENA study [1, 2] with the aim of sensitively capturing flares of all types as well as distinguishing severe flares. Mild and moderate flares are not discriminated in the cSFI, and this is a potentially important limitation in trials assessing drug efficacy since a moderate flare is likely to be more clinically significant and better able to discriminate treatment efficacy than a mild flare.
Furthermore, clinical observations have suggested the possibility that the medication criteria used in the cSFI may be problematic. If certain medication changes are made, this alone defines either mild/moderate or severe flares even in the absence of clinical criteria. These medication criteria were developed by consensus [3] and have never been tested for their relevance against clinical opinion. Furthermore, treatment standards evolve over time, making arbitrary rules that define disease by treatment extremely problematic in practice. The cSFI medication rules that define mild/moderate flares are (i) an increase in prednisone to <0.5 mg/kg/day and/or (ii) the addition of an NSAID or HCQ for SLE disease activity. Medication criteria defining severe flares are (i) an increase in prednisone to >0.5 mg/kg/day, and/or (ii) a doubling of prednisone for treatment of new or worse CNS lupus, vasculitis, nephritis, myositis, thrombocytopenia (<60 000/mm 3 ) or haemolytic anaemia [haemoglobin (Hg) <7 g/dl or a decrease in Hg >3 g/dl) and/or (iii) initiation of CYC, AZA, MTX or hospitalization. Several other medications have already come into widespread use since this instrument was devised and therefore, by convention, all immune suppressants or biologics can be treated the same as AZA or MTX. Nevertheless, they are missing from the definitions, creating confusion. It was understood when this instrument was devised that increases in or exchanges of medication for reasons other than disease activity (e.g. side effects, toxicity, cost, steroid sparing and patient preference) are not excluded as a definition of flare by these rules and could lead to the false description of a mild/moderate or severe flare. It might be assumed (although this assumption is not data driven) that such situations should be rare and might be considered as exceptions to the medication rules. Nevertheless, the frequency with which medication changes are made for patients who do not meet severe enough clinical criteria for a given degree of flare (e.g. increase in medication for persistent lupus disease activity or flares not clinically as severe as the instrument medication rules define them to be) also remain unknown. Such discrepancies might be less apparent in a clinical trial protocol in which medication changes are regulated, however, many flare assessments have been performed in clinical trial protocols at times during the study when medication changes are allowed. It is therefore important to understand the impact of cSFI medication rules on the differentiation of severe flare from mild/moderate flare or in differentiating any flare from persistent disease.
One process currently under way to address this issue is a novel comprehensive organ-based instrument defining mild, moderate and severe lupus flares that has recently been proposed by the SELENA study group [4] . This is a two-part index that includes rules to assign a clinical level of flare severity in different organs as mild vs moderate vs severe. There is a separate assessment for medication changes that provides potential for separately analysing the medication criteria [the revised SELENA flare index (SFI-R)]. This instrument has rarely been used in clinical trials to date and its validation process has yet to be completed. In the meantime, a better understanding of the strengths and limitations of the cSFI, which is currently available and will still be reported in pivotal trials for some time to come, would be helpful. Furthermore, if slight modifications to the relatively simple cSFI form or an analysis excluding the medication components might be helpful in the discrimination of flares, this might provide important information for trials that are currently in development and for exploratory analysis of results from ongoing or past clinical trial data.
Materials and methods
This study was performed through an analysis of data from the Oklahoma Lupus Cohort, which follows patients longitudinally for the study of biologic markers, clinical outcomes and clinical outcome measurements. The Ninety-one members of the Oklahoma Lupus Cohort were identified who met the 1997 modified ACR classification criteria for SLE [5] and had two clinic encounters at which the BILAG or SLEDAI had been scored at the time of each original visit and medication changes had been recorded. Other assessments were scored retrospectively based on the medical records, including some of the physician's global assessment (PGA) measurements. The hybrid SLEDAI is used for this cohort (identical to the SELENA-SLEDAI except for the scoring of proteinuria, which uses the SLEDAI-2K definition).
Flares were determined by the SELENA-SLEDAI flare composite (cSFI) [1, 2] adjusted to assess MMF, rituximab, LEF and calcineurin inhibitors by the same rules used for AZA, MTX and CYC. No patients taking belimumab were included in this study. Flares defined by the cSFI were compared with an experimental version (eSFI). The eSFI differed from the cSFI in that for each visit, all medication criteria were eliminated and a rater experienced in the care of lupus patients gave a global opinion (based on the medical record) to distinguish mild from moderate flares (see supplementary data, available at Rheumatology Online). A second clinician reviewed the assignment of eSFI flares as mild or moderate as well as the assessments that had been scored retrospectively, and marked any inconsistencies for comparison. These were reviewed and re-rated by consensus between the two assessors. Several activity measures were evaluated to compare the severity of disease in rater-assigned mild vs moderate flares and in cSFI flares that were or were not downgraded when medication rules were eliminated. These measures included PGA, SLEDAI, composite BILAG scores, number of BILAG-defined active organs (regardless of flare status) and an evaluation of the number of organs that were acutely flaring (based on the clinical descriptors indicating increased disease activity on the revised SFI (SFI-R). The SFI-R organ categories are mucocutaneous, musculoskeletal, cardiopulmonary, haematological, constitutional, renal, neurological and gastrointestinal.
Statistical analysis
Descriptive statistics [median, interquartile range (IQR)] were used to describe measures of disease activity and flare. Comparisons of those measures among different subgroups were performed by t-test or by a nonparametric MannWhitney rank sum test as applicable. SigmaPlot version 12.5 (Systat Software, San Jose, CA, USA) was used for all statistical analyses.
Results

Distribution of flares by the cSFI and eSFI
For the assessment of disease activity and flare, each of the 182 encounters with 91 patients was compared with the clinical state of the patient 1 month previously, consistent with the usual scoring for these instruments in trials. Patients might have flared at the baseline or follow-up visit, or both. Since analysis was based on individual flares rather than patients, our interpretation of results was not affected by having more than one flare. The distribution of encounters assessed by cSFI as no flare, mild/moderate flare and severe flare is shown in Table 1 .
After elimination of medication criteria, 41 of the 55 flares that had been defined as severe by the cSFI were downgraded, including 18 flares rated as moderate, 11 that were only rated as mild by clinical judgement and 13 in which there was no flare at all. Similarly, among 49 mild/moderate cSFI-defined flares, 15 (30%) were assessed as no flare by clinical criteria (eSFI). Thus 28 of 106 (26%) encounters clinically assessed as no flare (patients may have been either improving or unchanged) were arbitrarily designated as flares by the cSFI medication rules (of which 15 were upgraded to mild/ moderate and 13 to severe).
After elimination of the medication rules, the eSFI flares that did not meet the definition for severe were rated by an experienced clinician as either mild (n = 31) or moderate (n = 32). PGA (P = 0.023), global BILAG (P = 0.007) and the number of active A and B BILAG domains (P = 0.007) were higher in the flares designated as moderate than those rated as mild (MannWhitney rank sum test; Table 2 ), suggesting that the addition of a simple, global physician rating might help to discriminate those flares with more clinically significant disease activity within the mild/ moderate category.
Comparison of mild and moderate flares meeting clinical descriptors (eSFI) with those no longer counted as flares by eliminating medication criteria Fifteen of 49 (31%) flares defined as mild/moderate by the cSFI were downgraded to no flare when the medication criteria were eliminated (Table 1) . These were compared with the 34 flares that remained mild or moderate by the eSFI. Clinically defined mild and moderate flares (eSFI) had a higher disease activity by PGA (P < 0.001) than Deconstruction of the SELENA-SLEDAI flare index those defined as mild/moderate flare only by medication changes (MannWhitney sum rank test; Table 3 ). More SFI-R domains were flaring in those mild/moderate flares meeting eSFI once medication rules were eliminated (P < 0.001).
Prednisone was increased to <0.5 mg/kg in 93% of patients and new NSAIDs or HCQ were added, defining a mild/moderate flare on the cSFI, in 20% of encounters that did not meet any clinical criteria for flare, compared with 53% and 6%, respectively, of mild or moderate flares that met clinical criteria after eliminating medication criteria (Table 4) . Immunosuppressant dose was increased in 13% of encounters that did not meet any clinical criteria for flare and in 23% of mild or moderate flares that were not downgraded by elimination of medication rules. This suggests that medication changes are common in patients who may have persistent disease without an increase in disease activity.
Comparison of eSFI severe flares with encounters downgraded from severe flare after elimination of medication criteria Several disease activity measures were higher in those severe flares that remained by clinical grounds after medication rules were eliminated compared with those that were downgraded (MannWhitney rank sum test; Table 5 ), including measures of overall disease activity [PGA (P < 0.001), SLEDAI (P < 0.001), global BILAG (P < 0.001)], the number of active BILAG organs (P < 0.04) and the number of specifically worsening organs [SFI-R domains (P < 0.01)].
The dose of medication given did not necessarily distinguish the severity of clinical flare (Table 6 ). For example, prednisone was increased to >0.5 mg/kg/day in 15% of eSFI (clinically defined) severe flares compared with 25% of non-severe flares and was increased to <0.5 mg/kg/ day in 54% of eSFI-defined severe flares vs 40% of encounters that did not meet the clinical criteria for severe flare. New immunosuppressant therapy was added in 31% of eSFI-defined severe flares compared with 81% of flares that did not meet the clinical criteria for severe flares. Immunosuppressant dose was increased in 23% of severe flares and 5% of encounters that did not meet the clinical criteria for severe flares. It should be noted that immunosuppressants that had been discontinued due to non-compliance were restarted in 26% of the non-severe flare encounters (but none of eSFI severe flares). In the absence of any clinical flare, immunosuppressants or biologics were started in 11 encounters and prednisone dose was increased in 8, apparently for treatment of ongoing persistent disease.
Discussion
The cSFI was originally developed to sensitively detect flares of any kind and to differentiate severe flares in lupus patients who had entered that study with stable disease [3] . For the purposes of the SELENA trial, which was to assess the safety of exogenous oestrogens in patients with SLE, a distinction between mild and moderate flares was not a priority and the most sensitive possible definition of flare was valuable. Since the SELENA trials were completed, however, this index has been widely applied in interventional treatment trials. Here, the distinction between mild and moderate degrees of flare may be very important. Endpoints using only severe SFI flares seem to be more discriminatory than those evaluating the lumped category of mild/moderate [6] . The designation of severe Deconstruction of the SELENA-SLEDAI flare index flare has also been found to be more in agreement with expert opinion than assessments of all flares (including mild flares) [4] . Similarly, BILAG flares seem to provide better discrimination when evaluating new severe disease as opposed to one or more BILAG B scores, which can sometimes signify a very mild flare [7, 8] . On the other hand, severe flares are relatively rare and many studies may be underpowered to discriminate treatments based on severe flare rates. Therefore the optimal endpoint for power and discriminatory capacity might be to measure only moderate (clinically significant) or severe flares, which would necessitate distinguishing between mild and moderate flares. In short, the inclusion of mild flares in a flare assessment provides a greater sensitivity of flare detection (which was considered an asset in the SELENA trial), but those measures that are too sensitive to change in disease states may pick up a significant number of clinically inconsequential events that could obfuscate the discrimination between meaningfully effective treatments and placebo. An optimal, versatile instrument, then, would be able to discriminate mild, moderate and severe flares, allowing a study design to dictate which of these endpoints (alone or in combination) are most useful for a given purpose. In this analysis, considerable limitations are the retrospective scoring of flares by the cSFI and SFI-R instruments with reconstruction of missing data, i.e. some PGA scores, based on clinic notes. Comparative analysis of only the data that were complete would be valuable to convince one that missing data that were extracted or assessed at a later time did not bias the results; however, this has not been performed because of the formatting of our database. Since the PGA was a main parameter distinguishing mild and moderate flares by eSFI, a degree of circularity in the assignment of flare severity may have been inevitable. It is further possible that the distinction of eSFI flares to mild or moderate by a single assessor has allowed for standardization that is unusual in daily clinical practice.
Despite these limitations, the data presented here confirm that, without changing the range of symptoms described in the classic SELENA-SLEDAI mild/moderate category, adding one simple global rating (even one that is performed retroactively) that distinguishes moderate from mild flares produces a reasonable discrimination. Those flares designated as moderate had higher disease activity scores, higher PGA scores and more organs defined as worsening (see Table 2 ). Although the SFI-R has recently been devised as a more comprehensive flare instrument, which is currently undergoing testing by the SELENA and SLICC groups, our data suggest that the many trials that are beginning in the near future might benefit from using a small addition to the simpler classic flare index to differentiate between mild (and often clinically inconsequential) and moderate (more likely to be discriminatory) flares. In practice this might become operative with one extra checkbox on the form and would not prevent performance of the original classic analysis using the original categories.
The medication rules were originally added to the SFI in order to sensitively capture less typical flares of disease that might not be described in the index. The concept is reasonable that if medication is changed or added a patient might not be considered entirely stable, therefore the definition of flare was literally extended to include all patients in whom these medication rules applied. However, as the flare index began to be used in a range of clinical situations (including many interventional treatment trials), the use of arbitrary medication cut-offs to define the severity of a flare or even flare itself was recognized to be problematic in several circumstances. First, not all patients respond the same way to a given choice or dose of medication, thus one dose or choice cannot accurately describe the degree of flare for all people. Second, patients can have mild, moderate or even severe disease activity that is persistent or even partially improving, and although the degree of illness might warrant medication changes, it is not a flare at all [9] . The current data suggest that these situations arise with enough frequency to make arbitrary medication cut-offs misleading as independent definitions of flare. Finally, medication standards are rapidly evolving in this disease and although, as a patchwork intervention, it is common practice to handle new immunosuppressants and biologics the same as the original agents listed in the cSFI, this only underscores the difficulty in using preset treatment rules in measurement of disease flare. The situation may become more problematic if new safe biologics become available and are used more commonly for prevention than for flares. As time goes by, will an instrument with increasingly complex treatment rules require a yearly update? This would not be welcomed by those contemplating clinical studies, which last years at a time. For all of these reasons it seemed useful to determine the impact of eliminating the medication rules from the SFI. Fortunately, the problem of picking up atypical flares not defined by the instrument can be addressed with the use of the SELENA-SLEDAI PGA, which is incorporated into the instrument and can also define flares in the absence of the listed clinical features.
The medication rules can be eliminated from the scoring of the SFI in current (or even past) clinical trials without changing the form itself or preventing the more classic analysis from continuing to be performed. Our data suggest that if medication rules are eliminated, all degrees of flare select for patients who are both more ill than those whose flares were defined by medication changes alone and also have more organs that have worsened. We hypothesize that this will become a somewhat less sensitive instrument for the measurement of flares, but the preliminary data presented here suggest the possibility that the modified instrument will improve the discrimination between clinically meaningful and clinically less meaningful events. This type of measurement may improve the clarity of clinical trial results, but prospective analyses are warranted.
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